The uricosuric action of halofenate (MK-185) in patients with hyperuricemia or uncomplicated primary gout and hyperlipidemia

      This paper is only available as a PDF. To read, Please Download here.


      Significant serum uric acid reductions resulted from the oral administration of 500 and 1000 mg daily doses of halofenate in patients with hyperlipoproteinemia. Pretreatment serum uric acid levels averaged 8.5 mg/100 ml: serum uric acid levels during placebo control period averaged 7.7 mg/100 ml. At halofenate doses of 500 mg daily, the mean level fell to 5.6 mg/100 ml; after 1000 mg to 4.2 mg/100 ml. Urate clearance increased significantly at both dosage levels. Mean cholesterol levels decreased only slightly; triglyceride levels fell 16% from placebo levels on the larger dose of halofenate (1000 mg daily). Halofenate serum concentrations consistently reached a plateau by the 7th day of administration. There was an initial rapid decline in serum levels of halofenate immediately after discontinuance of the drug, but traces of it were still detectable one month later. Serum bilirubin levels decreased in all patients, possibly as a result of displacement of bilirubin from its plasma binding sites by halofenate. This study confirms the potent uricosuric action of this recently developed lipid-lowering drug.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Gilfillan J.L.
        • Hunt V.M.
        • Huff J.W.
        The hypolipemic properties of 2-acetoamidoethyl (p-chlorophenyl) (m-trifluoromethylphenoxy) acetate in the rat.
        in: 4th edition. Proc. Soc. Exp. Biol. Med.136. 1971: 1274-1276
        • Jain A.
        • Ryan J.R.
        • Hague D.
        • McMahon F.G.
        The effect of MK-185 on some aspects of uric acid metabolism.
        Clin. Pharmacol. Therap. 1970; 11: 551-557
        • Sirtori C.R.
        • Azarnoff D.L.
        Clinical evaluation of MK-185; a new hypolipidemic drug.
        J. Amer. Oil Chemists Soc. 1971; 48: 92A
        • Morgan J.P.
        • Bianchine J.R.
        • Hsu Tah-Hsiung
        • Margolis S.
        Hypolipidemic, uricosuric, and thyroxine-displacing effects of MK-185 (halofenate).
        Clin. Pharmacol. Therap. 1971; 12: 517-524
        • Duncan D.B.
        Multiple range and multiple F test.
        Biometrics. March, 1955;
        • Ostrander L.D.
        Alteration of factors predisposing to coronary heart disease.
        Ann. Intern. Med. 1968; 68: 1072-1077
      1. Hutchison, J. C., and Wilkinson, W. H., The dosage, form and mg/K response of halofenate (MK-185) on uric acid and serum lipids, To be published.

        • Hucker H.B.
        • Grady L.T.
        • Michniewicz B.M.
        • Stauffer S.C.
        • White S.E.
        • Maha G.E.
        • McMahon F.G.
        Metabolism of a new hypolipidemic agent, 2-acetamidoethyl (p-chlorophenyl) (m-trifluormethylphenoxy) acetate (halofenate) in the rat, dog, rhesus monkey and man.
        J. Pharmacol. Exp. Therap. 1971; 179: 359